Uppsala, January 24, 2024. OssDsign AB (publ.) today announces that the previously communicated outstanding 12-month results from the clinical study TOP FUSION have been published in the peer-reviewed journal Biomedical Journal of Scientific & Technical Research. The results show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with the novel nanosynthetic bone graft OssDsign Catalyst.
Karolinska Development s portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
OssDsign reports exceptional data from the clinical study TOP FUSION realtid.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from realtid.se Daily Mail and Mail on Sunday newspapers.
Uppsala, January 9, 2024. OssDsign AB today announces that positive data from the clinical study TOP FUSION has been submitted to a peer-reviewed scientific journal. Top-line results show a 93 %.
STOCKHOLM, SWEDEN, January 9, 2024. Karolinska Development AB announces that the portfolio company OssDsign reports positive data from the clinical study TOP FUSION. Top-line results show a 93%.